Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Clinical trial NCT01030900 · COMPLETED
Trial details
- NCT number
- NCT01030900
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-10-22
- Primary completion
- 2021-08-06
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.